Last reviewed · How we verify
Choriogonadotropin Alpha
At a glance
| Generic name | Choriogonadotropin Alpha |
|---|---|
| Also known as | ovidrel, hCG |
| Sponsor | Sports Medicine Research and Testing Laboratory |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles (NA)
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation (PHASE2)
- Transfer of Frozen Embryos in Natural Cycle: Evaluation of Impact of Spontaneous Versus HCG-triggered Ovulation on Pregnancy Rate (NA)
- Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulation?
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment (NA)
- Hormone Evaluation in Artificial Reproductive Technology (NA)
- Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
- Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Choriogonadotropin Alpha CI brief — competitive landscape report
- Choriogonadotropin Alpha updates RSS · CI watch RSS
- Sports Medicine Research and Testing Laboratory portfolio CI